Amoxicillin-Apotex

Main information

  • Trade name:
  • Amoxicillin-Apotex 250 mg/5mL Powder for oral suspension
  • Dosage:
  • 250 mg/5mL
  • Pharmaceutical form:
  • Powder for oral suspension
  • Units in package:
  • Bottle, plastic, HDPE, 100 mL
  • Class:
  • Prescription
  • Prescription type:
  • Prescription
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • DSM Sinochem Pharmaceuticals India Private Limited

Documents

Localization

  • Available in:
  • Amoxicillin-Apotex 250 mg/5mL Powder for oral suspension
    New Zealand
  • Language:
  • English

Therapeutic information

  • Therapeutic indications:
  • Amoxicillin is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:Upper Respiratory Infections:Otitis media, pharyngitis, sinusitis and tonsillitis. Lower Respiratory Infections:Bronchitis, bronchopneumonia and lobar pneumonia. Urinary Tract Infections:Cystitis, cysto-pyelitis, urethritis, and gonococcal urethritis. Prophylaxis:against ��-haemolytic (viridans group) and ��-haemolytic Streptococci before dental, oral or upper respiratory tract surgery or instrumentation. Prophylaxis:of bacterial endocarditis in patients with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular lesions, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemicpulmonary shunts, mitral valve prolapse with valvular regurgitation or mitral valve prolapse without valvular regurgitation but associated with thickening and/or redundancy of the valve

Other information

Status

  • Source:
  • Medsafe - Medicines Safety Authority - New Zealand
  • Authorization number:
  • 9711
  • Authorization date:
  • 06-04-2000
  • Last update:
  • 27-09-2017

3-12-2018

PMS-Amoxicillin (2018-12-03)

PMS-Amoxicillin (2018-12-03)

Health Canada

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

18-5-2018

Unauthorized prescription antibiotic drugs seized from Gigi's Market in Ottawa, ON, may pose serious health risks

Unauthorized prescription antibiotic drugs seized from Gigi's Market in Ottawa, ON, may pose serious health risks

Health Canada has seized four unauthorized drugs from Gigi’s Market, 23 Montreal Road, Ottawa, ON. The products (Ampicillin, Kamox, Medampi and Medomox) are labelled to contain antibiotic drugs (ampicillin or amoxicillin) that can only be dispensed by a healthcare professional to a patient with a valid prescription. The products listed below have not been evaluated by Health Canada for safety, effectiveness or quality and may pose serious health risks.

Health Canada

There are no news related to this product.